Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(4):292-295
DOI: 10.5428/pcar20180415
Clinical efficacy of montelukast sodium combined with budesonide formoterol powder inhalation in the treatment of bronchial asthma
1. ZHANG Rong(Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433,China 31955041@qq.com)
2. ZHAO JiaYi(Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433,China )
3. HAN YiPing(Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433,China yphan2006@163.com)
4. ZHANG JingXi(Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433,China )
5. BAI Chong(Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433,China )
ABSTRACT  Objective: To explore the efficacy of montelukast sodium combined with budesonide formoterol powder inhalation in the treatment of bronchial asthma. Methods: A total of 104 patients with bronchial asthma,who sought medical care in the Department of Respiratory and Critical Care Medicine, were randomly divided into the observation group (n=52) and the control group (n=52). The patients in the control group were treated with routine therapy and budesonide formoterol powder inhalation. The patients in the observation group were given montelukast sodium 10 mg once a day in addition to the treatment received by the control group. The clinical treatment efficiency, improvement of lung function,symptom relief and adverse drug reactions (ADRs) were compared between the two groups.Results: Total effective rate of the observation group was significantly higher than that of the control group(92.3% vs 69.2%),with statistical significance (P<0.01). Improvement of lung function and symptom relief time in the observation group were significantly better than those in the control group, also with statistical significance(P<0.01). In addition,there was no significant difference in the incidence of ADRs when comparisons were made between the two groups. Conclusion: Administration of montelukast sodium on the basis of budesonide formoterol powder inhalation in the treatment of bronchial asthma could quickly relieve clinical symptoms, improve pulmonary function significantly, with higher effective rate. For this reason, it is worth further clinical extension. However, incidence of ADRs demands further study.
Welcome to PCAR! You are the number 56 reader of this article!
Please cite this article as:
ZHANG Rong,ZHAO JiaYi,HAN YiPing,ZHANG JingXi,BAI Chong,. Clinical efficacy of montelukast sodium combined with budesonide formoterol powder inhalation in the treatment of bronchial asthma[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(4): 292-295.
References:
1. CAI GaoXiang, SU DongJu, LI BinFei. Effect of doxofylline combined with budesonide inhalation therapy for patients with acute exacerbation of bronchial asthma[J]. J Harbin Med Univ,2015,49(2):149-152.In Chinese with English abstract.
2. ZHANG JiaJia, HU ChiJun, ZHOU XiaoQin, et al. Effect of budesonide combined with montelukast sodium on cytokines,immune function in children with asthma[J]. Prog Mod Biomed,2017,17(3):550-553. In Chinese with English abstract.
3. LI Wen, NING Jun, SHEN ChangQing,et al. Effect of montelukast and budesonide on oxidative stress in children with asthma[J]. J Clin Pulm Med, 2017, 22(2):332-333,346. In Chinese with English abstract.
4. WEI YongQin. Clinical experience in the treatment of 100 children with bronchial asthma[J]. China Pract Med,2016,11(16):183-184. In Chinese.
5. TONG Yi, LIU LiFen, WANG Di. Comparison of the influence between budesonide monotherapy and combination of montelukast on serum total IgE of patients with bronchial asthma[J]. J Clin Pulm Med,2016,21(5):788-791. In Chinese with English abstract.
6. Arulparithi C S, Babu T A, Ravichandran C, et al. Efficacy of nebulised budesonide versus oral prednisolone in acute severe asthma[J]. Indian J Pediatr,2015,82(21):328-332.
7. DENG ShengYong, WU YanRong. Impact of montelukast on lung function and induced sputum IL-5 IFN-γ in children with bronchial asthma[J]. Hebei Med,2016,22(1):81-84. In Chinese with English abstract.
8. GUO HuiHuan, LIN ShaoLing. Effect of montelukast sodium on the detection of T lymphocyte subsets in children with bronchial asthma[J]. Heilongjiang Med J, 2015, 39 (8), 935-936. In Chinese with English abstract.
9. SHEN Ming, ZHOU HongYu, NI LiLi. Clinical application of budesonide/formoterol combined with montelukast in patients with bronchial asthma[J]. Chin Med J Metall Ind,2016,33(4):386-387. In Chinese with English abstract.
10. BU TaoRan. Observation of curative effect of Yunpibufei decoction combined with salbutamol by aerosol inhalation on chronic persistent bronchial asthma[J]. Mod J Integr Tradit Chin West Med,2016,25(8):832-835. In Chinese with English abstract.
11. Barve K S, Joshi J, Karkhanis V. Use of beclomethasone/budesonide and formoterol adjustable dose as single maintenance and rescue therapy in the management of bronchial asthma[J]. Indian J Allergy Asthma Immunol,2014,28(1):27-34.
12. Bateman E D, Goehring U M, Richard F, et al. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma[J]. J Allergy Clin Immunol,2016,138(1):142-149.
13. Jindal A, Suriyan S, Sagadevan S, et al. Comparison of oral montelukast and intranasal fluticasone in patients with asthma and allergic rhinitis[J]. J Clin Diagn Res,2016,10(8):OC6-OC10.
14. CAI JunQin. Analysis of 80 cases of acute bronchial asthma in children[J]. Qingdao Med J, 2017,49(2):110-112.In Chinese.
15. LU Wei, LU Chao, ZHANG ChengMing,et al.One mechanism of glucocorticoid action in asthma may involve the inhibition of IL-25 expression[J]. Exp Ther Med,2017,13(2): 657-661.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口